Market Filing: Topspin Fund L.P. Just Disclosed New Immune Design Corp Position

Market Filing: Topspin Fund L.P. Just Disclosed New Immune Design Corp Position

The New Topspin Fund L.P. Holding in Immune Design Corp

Topspin Fund L.P. filed with the SEC SC 13G/A form for Immune Design Corp. The form can be accessed here: 000114420416126239. As reported in Topspin Fund L.P.’s form, the filler as of late owns 12.4% or 3,098,239 shares of the -company.

Immune Design Corp stake is a new one for the and it was filed because of activity on December 31, 2015. We feel this shows Topspin Fund L.P.’s positive view for the stock.

Immune Design Corp Institutional Sentiment

Latest Security and Exchange filings show 58 investors own Immune Design Corp. The institutional ownership in Q3 2015 is high, at 71.74% of the outstanding shares. This is increased by 4148462 the total institutional shares. 17913947 were the shares owned by these institutional investors. In total 3 funds opened new Immune Design Corp stakes, 25 increased stakes. There were 7 that closed positions and 18 reduced them.

2 managers had the stock in their top Ten. Notable investors are: Proquest Associates Iv Llc..

Stuart Weisbrod Iguana Healthcare Management Llc is an institutional investor bullish on Immune Design Corp, owning 75000 shares as of Q3 2015 for 0.36% of its portfolio. Cormorant Asset Management Llc owns 189000 shares or 0.37% of its portfolio. FL Proquest Associates Iv Llc have 5.67% of their stock portfolio for 1962720 shares. Further, Sectoral Asset Management Inc reported stake worth 0.47% of its US stock portfolio. The CA Column Group L P owns 3161942 shares. Immune Design Corp is 100.00% of the manager’s US portfolio.

Business Profile

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA).

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment increased to 1.25 in 2016 Q2. Its up 0.21, from 1.04 in 2016Q1. The ratio improved, as 8 funds sold all Immune Design Corp shares owned while 16 reduced positions. 8 funds bought stakes while 22 increased positions. They now own 9.57 million shares or 12.34% less from 10.92 million shares in 2016Q1.

The New York-based Jpmorgan Chase & has invested 0% in Immune Design Corp (NASDAQ:IMDZ). Wells Fargo & Mn holds 0% or 4,208 shares in its portfolio. Moreover, Cubist Systematic Strategies Ltd Llc has 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 4,550 shares. Proquest Assoc Iv Limited Com last reported 6.51% of its portfolio in the stock. Panagora Asset Mngmt holds 0% or 96,644 shares in its portfolio. Teachers Advsr Inc reported 19,304 shares or 0% of all its holdings. Rhumbline Advisers last reported 10,089 shares in the company. Moreover, Springbok Cap Management Ltd Liability Com has 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 800 shares. Tower Limited Liability Corp (Trc), a New York-based fund reported 603 shares. Pnc Financial Services Grp Incorporated has invested 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ). Barclays Public Ltd Liability Corporation last reported 264 shares in the company. Alps Advsrs last reported 28,310 shares in the company. Point72 Asset Management Ltd Partnership last reported 0% of its portfolio in the stock. Manufacturers Life Insurance The accumulated 803 shares or 0% of the stock. Schwab Charles Invest Mngmt has 0% invested in the company for 16,243 shares.

Insider Transactions: Since July 15, 2016, the stock had 4 insider buys, and 0 sales for $10.26 million net activity. 800,000 shares with value of $5.00M were bought by COLUMN GROUP L P on Tuesday, September 20. The insider COLEMAN LEWIS W bought 40,000 shares worth $250,000. The insider Brady Stephen R bought 1,500 shares worth $10,255. Svennilson Peter bought 800,000 shares worth $5.00 million.

Analysts await Immune Design Corp (NASDAQ:IMDZ) to report earnings on November, 10. They expect $-0.68 earnings per share, down 83.78% or $0.31 from last year’s $-0.37 per share. After $-0.71 actual earnings per share reported by Immune Design Corp for the previous quarter, Wall Street now forecasts -4.23% EPS growth.

About 15,373 shares traded hands. Immune Design Corp (NASDAQ:IMDZ) has declined 24.28% since February 29, 2016 and is downtrending. It has underperformed by 36.49% the S&P500.

Immune Design Corp. is a clinical stage immunotherapy company. The company has a market cap of $199.54 million. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. It currently has negative earnings. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS.

Immune Design Corp (NASDAQ:IMDZ) Ratings Coverage

Out of 2 analysts covering Immune Design (NASDAQ:IMDZ), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $40 is the highest target while $17 is the lowest. The $28.50 average target is 269.65% above today’s ($7.71) stock price. Immune Design has been the topic of 4 analyst reports since August 18, 2015 according to StockzIntelligence Inc. Jefferies initiated it with “Buy” rating and $30 target price in Wednesday, September 9 report. Jefferies maintained the shares of IMDZ in a report on Wednesday, August 10 with “Buy” rating. Leerink Swann initiated it with “Outperform” rating and $40 target price in Tuesday, August 18 report.

More important recent Immune Design Corp (NASDAQ:IMDZ) news were published by: Quotes.Wsj.com which released: “News Immune Design Corp.IMDZ” on July 31, 2014, also Globenewswire.com published article titled: “Immune Design Announces Proposed Public Offering of Common Stock”, Globenewswire.com published: “Immune Design Announces Presentations at the 2016 American Society of Clinical …” on April 21, 2016. More interesting news about Immune Design Corp (NASDAQ:IMDZ) was released by: Globenewswire.com and their article: “Immune Design and Gritstone Oncology Announce Clinical Collaboration for …” with publication date: May 09, 2016.

According to Zacks Investment Research, “Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.”

IMDZ Company Profile

Immune Design Corp., incorporated on February 20, 2008, is a clinical-stage immunotherapy company. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment